Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Closed - Nasdaq Stockholm 07:59:43 2023-11-03 EDT			5-day change	1st Jan Change
0.1604 ^SEK	-1.11%		-.--%	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Market Cap	182M 18.11M 16.09M 15.02M 13.69M 25.82M 1.74B 26.06M 70.43M 890M 67.99M 66.52M 2.86B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 39.41M 35.02M 32.68M 29.79M 56.18M 3.79B 56.71M 153M 1.94B 148M 145M 6.22B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23-10-23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
23-10-20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
23-10-20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
23-10-19	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
23-10-16	Irras Obtains Extension for SEK20 Million Loan	MT
23-10-15	Irras extends SEK 20 million short-term loan	FW
23-10-02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
23-09-18	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
23-05-22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
23-05-21	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
23-02-20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

IRRS ABNPV Stock

Stocks

IRRAS

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRS ABNPV

Latest news: IRRS ABNPV

Analysts' recommendations: IRRS ABNPV

Press Releases: IRRS ABNPV

Quotes and Performance

Price Extremes

Managers and Directors: IRRS ABNPV

Medical Devices & Implants

Financials

Company Profile

23-10-20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
23-10-19	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
23-10-19	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
23-10-16	IRRAS publishes prospectus	AQ
23-10-15	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Griffen Stapp DFI	Director of Finance/CFO	40	2021-06-16
Sten Gustafsson IRC	Investor Relations Contact	-	2021-03-08
Adam Sampson PRN	Corporate Officer/Principal	58	2017-12-31

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	2015-05-31
Marios Fotiadis CHM	Chairman	53	2020-08-17
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	2017-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRS ABNPV	-1.11%	-.--%	-.--%	-8.86%	16.9M
ABBOTT LABORATORIES	+0.84%	-3.74%	-27.56%	+1.79%	169B
MEDTRONIC PLC	-0.07%	-2.55%	-11.59%	+12.86%	110B
STRYKER CORPORATION	+0.90%	+1.13%	-25.66%	+3.60%	106B
ESSILORLUXOTTICA	-1.24%	-0.76%	-49.50%	-12.08%	73.87B
CENCORA, INC.	-0.24%	+0.69%	+2.08%	+71.44%	58.98B
HOYA CORPORATION	-0.86%	+2.96%	+12.91%	+61.58%	51.28B
BECTON, DICKINSON AND COMPANY	-0.71%	-3.82%	-8.68%	-31.71%	48.16B
IDEXX LABORATORIES, INC.	+0.12%	-0.17%	-17.87%	+21.91%	40.84B
DEXCOM, INC.	-1.01%	-1.45%	+27.31%	-6.14%	32.21B
Average	-0.34%	-0.84%	-9.86%	+11.44%	69.02B
Weighted average by Cap.	+0.03%	-1.30%	-17.07%	+11.23%

	2023	2024
Net sales	42.88M 4.27M 3.8M 3.54M 3.23M 6.09M 411M 6.15M 16.62M 210M 16.04M 15.69M 674M	57.98M 5.78M 5.13M 4.79M 4.37M 8.24M 555M 8.31M 22.47M 284M 21.69M 21.22M 911M
Net income	-209M -20.81M -18.49M -17.26M -15.73M -29.67M -2B -29.95M -80.94M -1.02B -78.14M -76.45M -3.28B	-95.98M -9.56M -8.5M -7.93M -7.23M -13.63M -919M -13.76M -37.19M -470M -35.91M -35.13M -1.51B
Net Debt	43.85M 4.37M 3.88M 3.62M 3.3M 6.23M 420M 6.29M 16.99M 215M 16.4M 16.05M 689M	214M 21.3M 18.93M 17.67M 16.1M 30.37M 2.05B 30.65M 82.84M 1.05B 79.98M 78.25M 3.36B

3 years	0.16	0.18
5 years	0.11	5.09
10 years	0.11	47